Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 3
Submit an article Journal homepage
1,186
Views
3
CrossRef citations to date
0
Altmetric
Editorial

The latest prospects of investigational drugs for head and neck cancer

Olgun ElicinDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
&
Mahmut OzsahinDepartment of Radiation Oncology, University of Lausanne, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SwitzerlandCorrespondence[email protected]
Pages 265-268 | Received 09 Sep 2016, Accepted 03 Jan 2017, Published online: 10 Jan 2017

References

  • Pignon J-P, Le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.
  • Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578.
  • Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127.
  • Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
  • Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25(26):4096–4103.
  • Bossi P, Alfieri S. Investigational drugs for head and neck cancer. Expert Opin Investig Drugs. 2016;25(7):797–810.
  • Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33(29):3293–3304.
  • Curtis KK, Wong WW, Ross HJ. Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. Crit Rev Oncol Hematol. 2016;103:86–98.
  • Hutchinson L, Kirk R. High drug attrition rates–where are we going wrong? Nat Rev Clin Oncol. 2011;8(4):189–190.
  • Mehra R, Seiwert TY, Mahipal A, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012. ASCO Meet Abstr. 2016;34(15_suppl):6012.
  • Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.
  • Bentzen J, Toustrup K, Eriksen JG, et al.. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol. 2015;54(7):1001–1007.
  • Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN). A randomized phase III fac. J Clin Oncol. 2014;32(5s):suppl;abstr 6004.
  • Saba NF, Haigentz M, Vermorken JB, et al. Prevention of head and neck squamous cell carcinoma: removing the “chemo” from “chemoprevention.”. Oral Oncol. 2015;51(2):112–118.
  • Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066–4074.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.